AbbVie announced a $195 million investment to build a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago. This expansion supports domestic production for neuroscience, immunology, and oncology medicines, aiming to strengthen U.S. pharmaceutical innovation and supply chains. The facility is slated to be operational by 2027, reinforcing AbbVie's commitment to invest over $10 billion in U.S. capital projects to accelerate medical breakthroughs and economic growth, sustaining over 6,000 American jobs across multiple sites.